Cargando…

Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites

OBJECTIVE: IL-6 and catecholamines play roles in the pathophysiology of major depressive disorder (MDD). AIM: The present study investigated associations between plasma IL-6 and plasma catecholamine metabolites in patients with MDD. PARTICIPANTS AND METHODS: A total of 148 patients (male/female 65/8...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimura, Reiji, Kishi, Taro, Iwata, Nakao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752655/
https://www.ncbi.nlm.nih.gov/pubmed/31686824
http://dx.doi.org/10.2147/NDT.S195379
_version_ 1783452768873218048
author Yoshimura, Reiji
Kishi, Taro
Iwata, Nakao
author_facet Yoshimura, Reiji
Kishi, Taro
Iwata, Nakao
author_sort Yoshimura, Reiji
collection PubMed
description OBJECTIVE: IL-6 and catecholamines play roles in the pathophysiology of major depressive disorder (MDD). AIM: The present study investigated associations between plasma IL-6 and plasma catecholamine metabolites in patients with MDD. PARTICIPANTS AND METHODS: A total of 148 patients (male/female 65/83, age 49.5±12.1 years) who met the criteria for MDD based on the Diagnostic and Statistical Manual of Mental Disorders IV and 40 participants as healthy controls (HC; male/female 23/17, age 44.0±10.5 years) were enrolled in the present study. Plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and homovanillic acid (HVA) were analyzed using high-performance liquid chromatography, and plasma IL-6 levels were measured using ELISA. RESULTS: No correlations were observed among plasma IL-6 levels, MHPG levels, and HVA levels in patients with MDD. Plasma IL-6 levels in patients with MDD were significantly higher than in the HC. A positive correlation was found between plasma IL-6 levels and Hamilton Rating Scale for Depression-17 scores. CONCLUSION: No correlations existed between plasma IL-6 levels and plasma catecholamine metabolite levels in patients with MDD, and the severity of depressive state was related to plasma IL-6 levels in MDD.
format Online
Article
Text
id pubmed-6752655
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67526552019-11-04 Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites Yoshimura, Reiji Kishi, Taro Iwata, Nakao Neuropsychiatr Dis Treat Original Research OBJECTIVE: IL-6 and catecholamines play roles in the pathophysiology of major depressive disorder (MDD). AIM: The present study investigated associations between plasma IL-6 and plasma catecholamine metabolites in patients with MDD. PARTICIPANTS AND METHODS: A total of 148 patients (male/female 65/83, age 49.5±12.1 years) who met the criteria for MDD based on the Diagnostic and Statistical Manual of Mental Disorders IV and 40 participants as healthy controls (HC; male/female 23/17, age 44.0±10.5 years) were enrolled in the present study. Plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and homovanillic acid (HVA) were analyzed using high-performance liquid chromatography, and plasma IL-6 levels were measured using ELISA. RESULTS: No correlations were observed among plasma IL-6 levels, MHPG levels, and HVA levels in patients with MDD. Plasma IL-6 levels in patients with MDD were significantly higher than in the HC. A positive correlation was found between plasma IL-6 levels and Hamilton Rating Scale for Depression-17 scores. CONCLUSION: No correlations existed between plasma IL-6 levels and plasma catecholamine metabolite levels in patients with MDD, and the severity of depressive state was related to plasma IL-6 levels in MDD. Dove 2019-09-13 /pmc/articles/PMC6752655/ /pubmed/31686824 http://dx.doi.org/10.2147/NDT.S195379 Text en © 2019 Yoshimura et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yoshimura, Reiji
Kishi, Taro
Iwata, Nakao
Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites
title Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites
title_full Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites
title_fullStr Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites
title_full_unstemmed Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites
title_short Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites
title_sort plasma levels of il-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752655/
https://www.ncbi.nlm.nih.gov/pubmed/31686824
http://dx.doi.org/10.2147/NDT.S195379
work_keys_str_mv AT yoshimurareiji plasmalevelsofil6inpatientswithuntreatedmajordepressivedisordercomparisonwithcatecholaminemetabolites
AT kishitaro plasmalevelsofil6inpatientswithuntreatedmajordepressivedisordercomparisonwithcatecholaminemetabolites
AT iwatanakao plasmalevelsofil6inpatientswithuntreatedmajordepressivedisordercomparisonwithcatecholaminemetabolites